Patients with CD4 counts below 200 cells/mm3 who are not on preventative therapy are nine times more likely to develop PCP than patients on prophylactic trimethoprim-sulfamethoxazole (TMP-SMX) [2]. This evidence concerns the gene CD4 and pneumocystosis.